Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 22Thoracic 3Other hematologic neoplasm 3Genitourinary 3Gynecologic 2Dermatologic 2Sarcoma 1Plasma cell 1NET 1Lymphoid 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Mycosis Fungoides 1Lymphoma, T-Cell 1Hematologic Neoplasms 1

Interventions

Rituximab 689Cyclophosphamide 615Vincristine 285Etoposide 272Doxorubicin 271Cytarabine 230Prednisone 229Methotrexate 221fludarabine phosphate 189Filgrastim 187Dexamethasone 180fludarabine 176Lenalidomide 165Radiotherapy 128Melphalan 127Peripheral Blood Stem Cell Transplantation 123Busulfan 118Bendamustine Hydrochloride 116Granulocyte Colony-Stimulating Factor 113Bortezomib 112ibrutinib 111Mycophenolic Acid 110venetoclax 106Whole-Body Irradiation 106obinutuzumab 105Tacrolimus 105Gemcitabine 92zanubrutinib 81Specimen Handling 80Cyclosporine 76

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Isotretinoin × Lymphoid × Clear all
NCT00038376 2018-10-29

Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies

M.D. Anderson Cancer Center

Phase 2 Completed
56 enrolled
LymphoidOther hematologic neoplasm

Mycosis Fungoides, Lymphoma, T-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡